Logo

tepotinib

FDA Grants Full Approval to Merck KGaA's Tepmetko in Advanced METex14-Altered NSCLC

The drug garnered accelerated approval from the FDA in 2021, but the agency has now granted full approval based on additional data.

Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Premium

Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance. 

NICE Recommends Merck's Tepmetko for NSCLC Patients With METex14 Skipping Mutation

More than 700 people in England are now eligible to receive Tepmetko as either a first- or second-line treatment. 

Lung Cancer Research Foundation, MET Crusaders to Fund MET-Driven Cancer Research Projects

This year, LCRF and the patient advocacy group MET Crusaders plan to support two specific research projects into cancers driven by MET alterations.

Merck KGaA's Tepmetko Approved in Europe for NSCLC With MET Exon 14 Alterations

The drug was approved as a monotherapy for previously treated patients, a departure from approvals in the US and Japan for patients regardless of prior treatment.